Active Ingredient History

  • Now
Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. It was investigated as a treatment for relapsed or refractory peripheral T-cell lymphoma. Development was abandoned in 2015 due to poor clinical trial results.   Wikipedia

  • SMILES: COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25
  • Mol. Mass: 518.93
  • ALogP: 5.75
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
alisertib | alsertib | mln8237 | mln 8237 | mln-8237


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue